We stand at a critical juncture in psychiatric medicine. The recent phase III trial data from Definium and other research groups demonstrating meaningful anxiolytic and antidepressant effects of LSD-assisted therapy have reignited serious scientific discussion about psychedelics’ therapeutic potential. Yet as these compounds approach regulatory approval pathways, our field faces an urgent obligation: we must not allow enthusiasm for novel mechanisms to obscure the hard lessons of psychiatric pharmacotherapy’s troubled history.
The trial results themselves warrant scrutiny and respect. Multiple late-stage studies showing statistically significant and clinically meaningful improvements in anxiety and depression, particularly in treatment-resistant populations, represent genuine scientific progress. The putative mechanisms—rapid neuroplasticity, dissolution of rigid cognitive patterns, enhanced therapeutic alliance—offer theoretical appeal and preliminary empirical support. This is not hype. This is the beginning of serious medicine.
Yet I write this editorial precisely because it is serious. History instructs us with humility.
Consider the trajectories of selective serotonin reuptake inhibitors, which transformed psychiatry in the 1990s with compelling efficacy data, only to reveal over two decades problems with sexual dysfunction, withdrawal syndromes, and modest effect sizes in many populations. Or atypical antipsychotics, approved with confidence for bipolar disorder and major depression, which subsequently demonstrated metabolic and cardiovascular risks not fully captured in shorter trials. These were not failures of individual investigators but of systems: we approved compounds based on narrow efficacy windows, then learned their true benefit-risk profiles only through population-level experience.
Psychedelics present compounding complexities. Unlike conventional pharmaceuticals with clearly defined pharmacokinetics, these compounds operate through complex serotonergic and glutamatergic systems with effects that appear inseparable from the therapeutic context. The data we celebrate emerged from controlled, supervised administration with psychological support—precisely the conditions that maximize potential benefit while minimizing real-world risks. How these therapies perform in routine clinical practice, in patients with comorbid substance use disorders, in populations taking polypharmacy, across different cultural contexts—these questions remain largely open.
More pressing still is the question of equity and access. Psychedelic-assisted therapy, as currently trialed, is labor-intensive, requiring trained facilitators, controlled settings, and extended therapeutic contact. This is expensive. Without deliberate policy intervention, these therapies will become available first to affluent populations in major medical centers, potentially widening disparities in psychiatric care at precisely the moment we claim to offer breakthrough treatments. Our journals must demand that regulatory approvals be coupled with explicit funding mechanisms and training initiatives ensuring equitable access, or we risk creating a two-tiered system of psychiatric medicine.
I propose three concrete obligations for our field as regulatory pathways advance:
First, establish robust post-market surveillance frameworks now, before approval. The FDA’s accelerated approval pathways, while valuable for serious conditions, must be paired with mandatory registries tracking long-term outcomes, adverse events, and treatment trajectories across diverse populations. We cannot afford to discover problems retrospectively through case reports and adverse event monitoring alone.
Second, medical journals—including our own—must enforce a higher standard of evidence for psychedelic claims than we might for conventional agents. This reflects not bias but appropriate epistemic caution. Systematic reviews addressing publication bias, standardized outcome metrics, independent replication, and explicit discussion of mechanisms must precede enthusiasm. Single-site trials, however promising, warrant measured interpretation.
Third, funding agencies and regulatory bodies must condition approval on implementation science research. How do these therapies translate from specialized research centers to mental health">community mental health settings? What training is sufficient? What populations benefit most? These questions are not afterthoughts—they are prerequisites for responsible authorization.
I do not oppose psychedelic-assisted therapy’s regulatory pathway. The suffering caused by treatment-resistant anxiety and depression is real, and novel interventions deserve evaluation. But approval is not a destination; it is an authorization to learn at scale, under conditions of rigorous observation.
Our obligation as a medical community is to welcome genuine innovation while maintaining epistemic humility about its boundaries. Psychedelics may represent a meaningful advance in psychiatric care. They may also present novel risks we have not yet conceived. Only through transparent, systematic, equity-focused post-market surveillance can we distinguish between these possibilities.
The threshold we face is not merely regulatory. It is ethical. We must approve these therapies in ways that ensure they benefit patients, advance science, and correct rather than reproduce the inequities that have long marked psychiatric medicine.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
